A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
Purpose: To evaluate the treatment outcomes of aflibercept in patients with exudative age-related macular degeneration (AMD) resistant to other anti-vascular endothelial growth factor (VEGF) medications (bevacizumab, ranibizumab, and combination with or without dexamethasone and laser photocoagulati...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2014-04-01
|
| Series: | Delhi Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.7869/djo.51 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849314268067921920 |
|---|---|
| author | Kiran Turaka |
| author_facet | Kiran Turaka |
| author_sort | Kiran Turaka |
| collection | DOAJ |
| description | Purpose:
To evaluate the treatment outcomes of aflibercept in patients with exudative age-related macular degeneration (AMD) resistant to other anti-vascular endothelial growth factor (VEGF) medications (bevacizumab, ranibizumab, and combination with or without dexamethasone and laser photocoagulation).
Materials and Methods:
A retrospective chart review of 56 patients (112 eyes) of persistent and recurrent exudative AMD treated prior with bevacizumab, ranibizumab, bevacizumab+dexamethasone intravitreal injections with or without combination of laser treatment was performed. Data analysis included demographics and treatment modalities to evaluate the visual acuity (VA) outcome, stabilization of AMD (central foveal thickness, CFT) and drug side effects (elevated intraocular pressure, IOP).
Results:
The mean age of the patients was 77 (range: 55-89) years. The mean central foveal thickness on optical coherence tomography (OCT) was 294 µ (range: 80-585). Intravitreal aflibercept injections were given in both eyes in 10 patients and in 1 eye in 46 patients. The mean interval between aflibercept injections to the last follow-up (FU) visit was 1.7months (range: 0-7). F There was no statistically significant difference in visual acuity (p=0.6) after aflibercept injection, however VA was stable (median 20/60). The central foveal thickness had decreased significantly (p=0.005). Complete response to treatment was noted in 21 patients (41%). AMD was stable in 26 (50%) and persistent with no response in five patients (9%).
Conclusions:
Monthly intravitreal Aflibercept injections stabilized the exudative AMD in approximately half of the patients who had prior resistance to other anti-VEGF medications. |
| format | Article |
| id | doaj-art-bfa3be30464049c78fc231e42d8336fe |
| institution | Kabale University |
| issn | 0972-0200 2454-2784 |
| language | English |
| publishDate | 2014-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Delhi Journal of Ophthalmology |
| spelling | doaj-art-bfa3be30464049c78fc231e42d8336fe2025-08-20T03:52:29ZengWolters Kluwer Medknow PublicationsDelhi Journal of Ophthalmology0972-02002454-27842014-04-0124424124410.7869/djo.51A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF AgentsKiran TurakaPurpose: To evaluate the treatment outcomes of aflibercept in patients with exudative age-related macular degeneration (AMD) resistant to other anti-vascular endothelial growth factor (VEGF) medications (bevacizumab, ranibizumab, and combination with or without dexamethasone and laser photocoagulation). Materials and Methods: A retrospective chart review of 56 patients (112 eyes) of persistent and recurrent exudative AMD treated prior with bevacizumab, ranibizumab, bevacizumab+dexamethasone intravitreal injections with or without combination of laser treatment was performed. Data analysis included demographics and treatment modalities to evaluate the visual acuity (VA) outcome, stabilization of AMD (central foveal thickness, CFT) and drug side effects (elevated intraocular pressure, IOP). Results: The mean age of the patients was 77 (range: 55-89) years. The mean central foveal thickness on optical coherence tomography (OCT) was 294 µ (range: 80-585). Intravitreal aflibercept injections were given in both eyes in 10 patients and in 1 eye in 46 patients. The mean interval between aflibercept injections to the last follow-up (FU) visit was 1.7months (range: 0-7). F There was no statistically significant difference in visual acuity (p=0.6) after aflibercept injection, however VA was stable (median 20/60). The central foveal thickness had decreased significantly (p=0.005). Complete response to treatment was noted in 21 patients (41%). AMD was stable in 26 (50%) and persistent with no response in five patients (9%). Conclusions: Monthly intravitreal Aflibercept injections stabilized the exudative AMD in approximately half of the patients who had prior resistance to other anti-VEGF medications.https://journals.lww.com/10.7869/djo.51afliberceptbevacizumabmacular degenerationranibizumabvascular endothelial growth factor |
| spellingShingle | Kiran Turaka A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents Delhi Journal of Ophthalmology aflibercept bevacizumab macular degeneration ranibizumab vascular endothelial growth factor |
| title | A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents |
| title_full | A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents |
| title_fullStr | A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents |
| title_full_unstemmed | A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents |
| title_short | A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents |
| title_sort | new anti vegf inhibitor aflibercept treatment outcomes of neovascular macular degeneration refractory to other anti vegf agents |
| topic | aflibercept bevacizumab macular degeneration ranibizumab vascular endothelial growth factor |
| url | https://journals.lww.com/10.7869/djo.51 |
| work_keys_str_mv | AT kiranturaka anewantivegfinhibitoraflibercepttreatmentoutcomesofneovascularmaculardegenerationrefractorytootherantivegfagents AT kiranturaka newantivegfinhibitoraflibercepttreatmentoutcomesofneovascularmaculardegenerationrefractorytootherantivegfagents |